Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), bought 5,000 shares at $0.68 ($3K) on 2023-05-16, disclosed to the SEC on 2023-05-18.
Open-market purchase of $3k TSHA by President and Head of R&D. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| TSHA | SELL | 2026-01-27 | $547K | — | Filing → |
| TSHA | SELL | 2026-01-14 | $942K | — | Filing → |
| TSHA | SELL | 2025-12-01 | $3.4M | — | Filing → |